This study sought to determine the evolution of the mutational status of EZH2 and CD79B over time in different samples from the same patient in a cohort of B-cell NHLs, through use of a customized multiplex mutation assay. This evidence concerns the gene CD79B and B-cell non-Hodgkin lymphoma.